Abstract 6454: Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study.
用户q8cvWnyP9yLk
1个月前
77
10
已关闭
DOI:
文献链接:
其他信息:

